N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease

Name: N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease
Published: 2026
License: Public Domain

Haukeland University Hospital · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

dementia mildcognitiveimpairment

alzheimer disease (ad), alzheimer's disease (ad), mild cognitive impairment, nicotinamide riboside, dementia, placebo controlled, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease

Related documents